Evidence map›Paper›PMID 34163576›Full record

ArticleWorld journal of gastrointestinal oncology2021

Serum vascular endothelial growth factor as a tumor marker for hepatocellular carcinoma in hepatitis C virus-related cirrhotic patients.

Ahmed Alzamzamy, Huda Elsayed, Mona Abd Elraouf, Hanan Eltoukhy, Tarek Megahed, Ashraf Aboubakr

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastrointestinal oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Ahmed AlzamzamyDepartment of Gastroenterology and Hepatology, Military Medical Academy, Cairo 11841, Egypt.
Huda ElsayedDepartment of Internal Medicine, Faculty of Medicine for Girls, Al-Azhar University, Cairo 11311, Egypt.
Mona Abd ElraoufDepartment of Internal Medicine, Faculty of Medicine for Girls, Al-Azhar University, Cairo 11311, Egypt.
Hanan EltoukhyDepartment of Internal Medicine, Faculty of Medicine for Girls, Al-Azhar University, Cairo 11311, Egypt.
Tarek MegahedDepartment of Clinical Pathology, Military Medical Academy, Cairo 11311, Egypt.
Ashraf AboubakrDepartment of Gastroenterology and Hepatology, Military Medical Academy, Cairo 11841, Egypt.
Al-Azhar University · EGMilitary Medical Academy · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatocellular carcinoma (HCC) accounts for 8.2% of all cancer-related deaths worldwide. Being a vascular tumor, vascular endothelial growth factor (VEGF) plays a vital role in HCC pathogenesis, growth, and spread.

aimTo determine the accuracy of serum VEGF and VEGF/platelet (PLT) as tumor markers in the early detection of HCC cases in patients with hepatitis C virus (HCV)-related liver cirrhosis.

methodsWe conducted a case-control study with HCV patients from the outpatient and inpatient hepatology clinics. Patients were classified into three groups: (1) HCC group; (2) Cirrhosis group; and (3) HCV without cirrhosis (control group). Patients were clinically evaluated, and blood samples were drawn for the analysis; serum VEGF levels were measured by a specific VEGF human recombinant enzyme-linked immunosorbent assay kit. Data from the three study groups were compared by the one-way analysis of variance or Kruskal-Wallis test. Receivers operating characteristic curves were constructed to determine the optimal cut-off values of alpha fetoprotein (AFP), VEGF, and VEGF/PLT that provided the best diagnostic accuracy. The sensitivity and specificity at the optimal cut-off value of each biomarker were then calculated.

resultsThis study included one hundred patients (HCC, cirrhosis, and control groups:

conclusionIn HCV patients, serum VEGF and VEGF/PLT separately or in combination with AFP are reliable biomarkers for early and accurate HCC diagnosis.

Indexed as

BiomarkersDiagnosisHepatocellular carcinomaVascular endothelial growth factor

Identifiers

PMID34163576
PMCPMC8204351
OpenAlexW3167289731

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.